Lucentis: Clinical Trials

63 trials of Lucentis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

63 completed. 63 Phase 2, 21 Phase 1, 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 263Completed 63
Phase 121Completed 21
Phase 34Completed 4

Follow Lucentis: new trials by email Literature Review of Lucentis trials Research Report on Lucentis

Trials (filtered) newest first · largest first

All 63 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema
Vamikibart, Ranibizumab, Sham Procedure - Diabetic Macular Edema
Phase 2CompletedHoffmann-La Roche3942021-12-312026-05-11
A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema
Vamikibart, Ranibizumab, Sham Procedure - Diabetic Macular Edema
Phase 2CompletedHoffmann-La Roche1872021-12-172025-10-16
601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
601 1.25mg, Ranibizuman 0.5 mg - Branch Retinal Vein Occlusion
Phase 2CompletedSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.602021-01-282025-06-27
601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)
601 1.25mg, Ranibizuman 0.5 mg - Central Retinal Vein Occlusion
Phase 2CompletedSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.602021-01-272025-06-27
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
LKA651, Lucentis - Diabetic Macular Edema
Phase 2CompletedNovartis Pharmaceuticals912019-05-242024-06-20
Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD
ALS-L1023, Ranibizumab, Placebo - Age-Related Macular Degeneration
Phase 2CompletedAngioLab, Inc.1262018-12-072022-08-11
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
OPT-302, ranibizumab, sham intravitreal injection - Neovascular Age-related Macular Degeneration
Phase 2CompletedOpthea Limited3662017-11-062021-01-12
ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
Avacincaptad Pegol, Lucentis - Neovascular Age-related Macular Degeneration
Phase 2CompletedOphthotech Corporation642017-10-112025-06-10
Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF
Ranibizumab Injection [Lucentis] - Exudative Age Related Macular Degeneration
Phase 2CompletedSoutheast Clinical Research Associates, LLC202017-10-012020-10-22
Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects
2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis - Age-Related Macular Degeneration
Phase 2CompletedSanten Inc.762017-07-052021-07-13
A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema
Faricimab, Ranibizumab - Diabetic Macular Edema
Phase 2CompletedHoffmann-La Roche2292016-04-272020-09-25
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
Faricimab, Ranibizumab, Sham Procedure - Choroidal Neovascularization
Phase 2CompletedHoffmann-La Roche2732015-08-112020-11-12
The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates
ranibizumab 0.3mg - Diabetic Macular Edema, Hard Lipid Exudates
Phase 1 / Phase 2CompletedSouth Coast Retina Center; Carson, McBeath, Boswell, Inc.252015-08-012021-07-08
Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration
Ranibizumab 0.5mg - Age-related Macular Degeneration
Phase 1 / Phase 2CompletedLeonard Feiner, MD, PhD42015-05-012018-08-28
A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
Avacincaptad Pegol - Idiopathic Polypoidal Choroidal Vasculopathy
Phase 2CompletedOphthotech Corporation42015-03-122025-03-20
A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)
ASP8232, ranibizumab, Placebo - Diabetes Mellitus, Diabetic Macular Edema
Phase 2CompletedAstellas Pharma Europe B.V.962015-01-122024-10-31
Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME
Ranibizumab 0.3 mg, Aflibercept 2.0 mg - Diabetic Macular Edema
Phase 2CompletedArshad Khanani1012015-01-012019-04-26
Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
0.5 mg ranibizumab, Targeted Retinal Photocoagulation (TRP) - Radiation Retinopathy
Phase 2CompletedGreater Houston Retina Research402014-09-232021-03-25
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
Ranibizumab 0.5mg - Age-related Macular Degeneration
Phase 1 / Phase 2CompletedSouthern California Desert Retina Consultants, MC1082014-09-172022-08-25
Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity
ranibizumab - Retinopathy of Prematurity (ROP)
Phase 2CompletedUniversity Hospital Freiburg192014-08-012017-03-09

Showing 20 of 63. Sign in to see all of them.

Conditions studied

Macular Degeneration (16)  ·  Macular Edema (7)  ·  Retinal Vein Occlusion (7)  ·  Choroidal Neovascularization (6)  ·  Diabetic Retinopathy (6)  ·  Polypoidal Choroidal Vasculopathy (5)  ·  Diabetes Mellitus (3)  ·  Edema (3)  ·  Wet Macular Degeneration (3)  ·  Pseudoxanthoma Elasticum (2)  ·  Retinal Detachment (2)  ·  Retinal Diseases (2)  ·  Vision Disorders (2)  ·  Vitreous Hemorrhage (2)  ·  Angioid Streaks (1)

Sponsors

Hoffmann-La Roche (4)  ·  Ophthotech Corporation (3)  ·  Arshad Khanani (2)  ·  California Retina Consultants (2)  ·  Jaeb Center for Health Research (2)  ·  Johns Hopkins University (2)  ·  Quark Pharmaceuticals (2)  ·  Southeast Retina Center, Georgia (2)  ·  Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (2)  ·  University Hospital, Bonn (2)  ·  University of Sao Paulo (2)  ·  Aerpio Therapeutics (1)  ·  AngioLab, Inc. (1)  ·  Astellas Pharma Europe B.V. (1)  ·  Barnes Retina Institute (1)

Countries

United States (46)  ·  Canada (5)  ·  Germany (5)  ·  South Korea (5)  ·  Spain (5)  ·  United Kingdom (5)  ·  Israel (4)  ·  Poland (4)  ·  Czechia (3)  ·  Puerto Rico (3)  ·  Argentina (2)  ·  Brazil (2)  ·  China (2)  ·  Hungary (2)  ·  Latvia (2)

Top investigators

Dennis M. Marcus, M.D. (2)  ·  Hendrik PN Scholl, MD, MA (2)  ·  Abdhish Bhavsar, MD (1)  ·  Adam R. Glassman, MS (1)  ·  Allen Ho, MD (1)  ·  Amy C Schefler, MD (1)  ·  Andreas Stahl, MD (1)  ·  Andrew Strong, Ph.D (1)  ·  Arshad Khanani, MD (1)  ·  Arshad M Khanani, MD (1)  ·  Arthur Korotkin, M.D. (1)  ·  Christina J. Flaxel, MD (1)  ·  Dante Pieramici, MD (1)  ·  David Callanan, MD (1)

Results publications

PMID 30957581, PMID 17367957, PMID 18214740, PMID 20163368, PMID 20417925, PMID 20856107, PMID 20877651, PMID 20885313, PMID 21232078, PMID 21334595, PMID 21681707, PMID 21704964, PMID 21742303, PMID 21915047, PMID 21955635, PMID 22081150, PMID 22357391, PMID 22882007, PMID 22990319, PMID 23187164, PMID 23370902, PMID 23486999, PMID 23544200, PMID 23777441, PMID 24026871, PMID 24326333, PMID 24335454, PMID 24923076, PMID 24923077, PMID 24967201, PMID 24982728, PMID 25001321, PMID 25019269, PMID 25390730, PMID 25633882, PMID 27836430, PMID 29127949, PMID 29309486, PMID 29729809, PMID 30905643, PMID 31388454, PMID 32303499, PMID 32729888, PMID 34201045, PMID 34463842, PMID 36754174, PMID 37422192, PMID 37868796, PMID 38758639, PMID 40522203

NIH funding

2018 (1), U10EY014231 (1), U10EY018817 (1)